Aptevo Therapeutics (Aptevo Therapeutics) FCF Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Aptevo Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Aptevo Therapeutics's Free Cash Flow for the three months ended in Dec. 2023 was $-5.25 Mil. Aptevo Therapeutics's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Therefore, Aptevo Therapeutics's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

As of today, Aptevo Therapeutics's current FCF Yield % is -462.72%.

The historical rank and industry rank for Aptevo Therapeutics's FCF Margin % or its related term are showing as below:

During the past 11 years, the highest FCF Margin % of Aptevo Therapeutics was -105.18%. The lowest was -682.43%. And the median was -260.17%.

APVO's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -148.935
* Ranked among companies with meaningful FCF Margin % only.

Aptevo Therapeutics FCF Margin % Historical Data

The historical data trend for Aptevo Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptevo Therapeutics FCF Margin % Chart

Aptevo Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-682.43

-182.17

-676.01

Aptevo Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Aptevo Therapeutics's FCF Margin %

For the Biotechnology subindustry, Aptevo Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aptevo Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aptevo Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Aptevo Therapeutics's FCF Margin % falls into.

Aptevo Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Aptevo Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-11.73	/	0
	=	%

Aptevo Therapeutics's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-5.253	/	0
	=	%

Aptevo Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Aptevo Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Aptevo Therapeutics (Aptevo Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptevo Therapeutics Inc (NAS:APVO) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

AP8N:Germany

Address

2401 4th Avenue, Suite 1050, Seattle, WA, USA, 98121

Website

https://www.aptevotherapeutics.com

Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Executives

Daphne Taylor	officer: SVP, CFO	3303 MONTE VILLA PARKWAY, BOTHELL WA 98021
Kevin C Tang	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Soyoung Kwon	officer: See Remarks	APTEVO THERAPEUTICS INC., 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Tang Capital Management Llc	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Partners Lp	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Randy Joe Maddux	officer: Senior VP, Operations	2401 4TH AVENUE, SUITE #1050, SEATTLE WA 98121
Fuad El-hibri	director	2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850
Daniel Abdun-nabi	director	400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879
Marvin L White	director, officer: President and CEO	2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850
Barbara Lopez Kunz	director	2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Zsolt Harsanyi	director	2273 RESEARCH BLVD., SUITE 400, ROCKVILLE MD 20850
Grady Iii Grant	director	2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Shawnte Mitchell	officer: SVP, GC and Corporate Affairs	5959 HORTON STREET, SUITE 500, EMERYVILLE CA 94608
Michael Adelman	officer: SVP, Commercial Operations	2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Jane A Gross	officer: See Remarks	2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121